The tiny fat-bubble delivery vehicle that wraps and protects an mRNA vaccine — carrying the genetic instructions safely into the patient's cells.
Naked mRNA is fragile: enzymes in the blood degrade it within minutes, and on its own it can't cross a cell's membrane to get inside. A lipid nanoparticle (LNP) solves both problems. It's a roughly 80–100 nanometre sphere of lipids that encapsulates the mRNA, shields it from degradation, and ferries it into cells — the same delivery technology that made the COVID-19 mRNA vaccines possible.
An LNP is built from four lipid components, and the key one is the ionizable lipid. It's electrically neutral in the bloodstream (which keeps the particle safe and non-toxic), but turns positively charged inside the cell's acidic endosome — that charge flip is what lets the particle break open and release its mRNA into the cytoplasm, where the cell's machinery can read it. The other three components (a helper phospholipid, cholesterol, and a PEG-lipid) control the particle's structure, stability, and how long it circulates.
For neoantigen vaccines this is more than plumbing. The LNP determines where the mRNA actually goes (biodistribution), how efficiently the encoded neoantigens get expressed, and how much the formulation itself stimulates the immune system — LNPs have an intrinsic adjuvant effect. Tuning the ionizable lipid to steer delivery toward lymph nodes and antigen-presenting cells, rather than the liver where LNPs naturally accumulate, is an active area of design and an increasing focus for AI-driven lipid and formulation optimization.
A lipid nanoparticle (LNP) is a tiny fat-based sphere — about 80–100 nanometres across — that encapsulates and protects mRNA, then carries it into the body's cells. It is the delivery vehicle behind mRNA vaccines, including the COVID-19 vaccines and personalized mRNA cancer vaccines.
On its own, mRNA is destroyed by enzymes in the blood within minutes and cannot cross a cell's membrane to get inside. The lipid nanoparticle shields the mRNA from degradation and delivers it into cells, where the cell's machinery can translate it into the encoded neoantigen proteins.
The ionizable lipid is the key component of a lipid nanoparticle. It stays electrically neutral in the bloodstream — which keeps the particle stable and low-toxicity — but becomes positively charged inside the cell's acidic endosome. That charge switch lets the particle break open and release its mRNA into the cell, the step that makes delivery work.